A New Pharmaceutical Company Repurposing Dronabinol For Obstructive Sleep Apnoea

(10 minutes)

About

ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on 11th January 2023 by RespireRx as an unlisted public company for the purpose of discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including sleep related breathing disorders such as obstructive sleep apnoea (“OSA”).

Automated Slide Deck

Our Parent Company, RespireRx Pharmaceuticals Inc., Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Improve Bladder Function in Patients with Spinal Cord Injury

May 29, 20249 min read

Our Parent Company, RespireRx Pharmaceuticals Inc., Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Feb 13, 202410 min read

Our Parent Company, RespireRx Pharmaceuticals Inc., Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

Jan 22, 20249 min read

RespireRx and Will Clodfelter to Collaborate on Business Development

Dec 11, 20239 min read

Repurposing Dronabinol for OSA

About Dronabinol

Dronabinol was first approved in the United States in 1985 and is currently approved for anorexia associated with AIDS and chemotherapy induced nausea and vomiting. We're developing dronabinol for OSA.

Obstructive Sleep Apnoea

Obstructive Sleep Apnoea (OSA) is associated with decreased quality of life, and significant functional impairment. According to an August 2019 publication in Lancet Respiratory Medicine, afflicts more than 90 million people in the United States, Australia, Germany and the United Kingdom.

Clinical Trials

ResolutionRx has obtained the rights from RespireRx, to develop and commercialize cannabinoids such as dronabinol for sleep related and other breathing disorders.